Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, a synthetic biotechnology company, reported strong financial results for Q4 and full-year 2021. Consumer revenue hit a record $32.2 million, a remarkable 86% increase year-over-year, driven by brands like Biossance and new launches such as JVN and Rose Inc. Technology access revenue also rose 54% to $32.6 million. Despite a 19% decline in total revenue due to one-off strategic transactions, core revenue grew 68% to $64.8 million. The company anticipates doubling total revenue in 2022, supported by operational improvements and a strong consumer brand strategy.
Amyris, a leading synthetic biotechnology company, announced its participation in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 1:30 pm ET. The event will focus on the company's Lab-to-Market™ technology platform, which drives sustainable consumption in the Clean Health & Beauty and Flavors & Fragrances sectors. A live webcast of the presentation and a replay will be available on the company's Investor Relations website. Amyris products reach over 300 million consumers and are featured in more than 20,000 items worldwide.
Amyris, Inc. (Nasdaq: AMRS) will release its financial results for Q4 and full year 2021 on March 1, 2022, before market opening. CEO John Melo and CFO Han Kieftenbeld will host a conference call at 6:00 a.m. PT (9:00 a.m. ET) to discuss these results and the company's progress. Attendees can access the live webcast through the Investor Relations website. Amyris focuses on sustainable consumption through its Lab-to-Market™ technology, supplying ingredients to major brands and catering to over 300 million consumers worldwide.
Amyris, Inc. (Nasdaq: AMRS) has successfully acquired EcoFabulous, a clean beauty brand targeted at Gen Z consumers, as part of its strategy to enhance growth in the sustainable beauty market. The acquisition complements Amyris' existing consumer brands, which include Rose Inc., JVN, Biossance, Pipette, and Purecane. Furthermore, the company has commenced production at its Reno, Nevada facility ahead of schedule, aiming for product sales to begin in Q3 2022. This move is expected to reduce reliance on third-party manufacturers and improve supply chain efficiency.
Amyris, a synthetic biotechnology company, has appointed Ana Dutra to its Board of Directors, effective January 21, 2022. With over 30 years of experience in global acquisitions and growth strategies, Dutra's expertise is expected to enhance shareholder value. CEO John Melo expressed optimism about her contributions, highlighting her leadership and operational depth. Dutra's background includes significant roles at major corporations, as well as experience in digital technology and ESG initiatives. This appointment comes as Amyris aims to leverage its Lab-to-Market platform for sustainable product innovation.
Amyris, a leading synthetic biotechnology company, announced an agreement to acquire MenoLabs, a women-founded wellness brand, to enhance its entry into the menopause market. This strategic acquisition aims to accelerate growth and establish leadership in a rapidly expanding market, valued at $15 billion and projected to reach $23 billion by 2028. MenoLabs offers all-natural products for menopause symptoms and generates recurring revenue through its subscription model. The acquisition is expected to contribute approximately $30 million in revenue in the first year.
Amyris, a leading synthetic biotechnology company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 am ET. This conference serves as a key platform for industry leaders, attracting significant attention from investors and analysts. A live webcast and replay of the presentation will be accessible on Amyris' Investor Relations page. The company focuses on sustainable ingredients in Clean Health & Beauty and Flavors & Fragrances, reaching over 300 million consumers.
Amyris and ImmunityBio have finalized their joint venture to commercialize a next-generation COVID-19 vaccine. This collaboration aims to leverage their combined strengths in vaccine technology and manufacturing capabilities. They plan to begin human trials and seek regulatory approval to deliver the vaccine by 2022, targeting underserved areas affected by vaccine accessibility challenges. The partnership aims to provide robust immunity against COVID-19 variants and adapt to future viruses. Further updates on trial outcomes will be provided as they become available.
Amyris, Inc. (Nasdaq: AMRS) has finalized a joint venture with Minerva Foods to improve the sustainability of animal protein production. The collaboration targets the Brazilian meat export industry, focusing on developing new molecules for reducing carbon intensity and creating sustainable packaging solutions. Regulatory approvals are in place, with expected first license revenue for Amyris by year-end 2021 and initial commercial production slated for 2022. The partnership aims to disrupt the animal protein market while enhancing Amyris' market reach and technology application.
Amyris, a synthetic biotechnology leader, reported unprecedented sales during Black Friday week, achieving over $10 million in consumer sales, doubling last year's figures. This week marked a record-breaking 791,000 visits to its websites, with about 50% of sales generated online. CEO John Melo highlighted successful navigation of supply chain challenges and emphasized the company's commitment to advancing its COVID-19 RNA vaccine trials in South Africa, aiming for regulatory approval to aid global vaccine access.
